Monthly Archives: January 2023

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

By Sharon Deveson Kell|2023-01-17T08:22:55+00:0017 Jan 2023|Drug treatments|

In this study, real world data is used to compare [...]

Read More

Comments Off on Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

• 

Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

By Sharon Deveson Kell|2023-01-12T15:18:26+00:0012 Jan 2023|Drug treatments|

A recent paper published in The Oncologist has shown that [...]

Read More

Comments Off on Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

• 

Does neoadjuvant therapy improve outcomes in localised kidney cancer?

By Sharon Deveson Kell|2023-01-12T09:51:58+00:0012 Jan 2023|Drug treatments|

At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]

Read More

Comments Off on Does neoadjuvant therapy improve outcomes in localised kidney cancer?

• 

BioNTech forms alliance with UK government for cancer immunotherapies

By Sharon Deveson Kell|2023-01-06T16:25:12+00:006 Jan 2023|Drug treatments|

BioNTech, the company who developed the COVID-19 mRNA vaccine, is [...]

Read More

Comments Off on BioNTech forms alliance with UK government for cancer immunotherapies

• 

CA-125 biomarker for renal medullary carcinoma

By Sharon Deveson Kell|2023-01-03T13:00:45+00:003 Jan 2023|Subtypes of RCC|

Renal medullary carcinoma (RMC) is very rare and aggressive subtype [...]

Read More

Comments Off on CA-125 biomarker for renal medullary carcinoma